INmune Bio stock holds at USD 1.93 as filing plans advance

Published on 10/04/2026 at 23:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

INmune Bio stock heads into a regulatory milestone after a Q2 loss of USD 1.3 million. Management targets a UK filing in Q4 2026, with USD 18.4 million in cash at June 30.

INMB, US45782T1051, Illustration mit AI erstellt.

INmune Bio (ISIN US45782T1051) stock closed at USD 1.93 on Nasdaq on October 2, 2026, leaving the shares 25.8 percent below the 52-week high of USD 2.60. The latest company update centers on a planned UK regulatory filing for Ebstrocel, the lead CORDStrom program.

UK filing path takes center stage

StockTitan reported on September 9, 2026, that INmune Bio plans a UK Marketing Authorization Application for CORDStrom in 2026, followed by European and US submissions in 2027. The company is also advancing XPro1595 in a proposed adaptive Phase 2b/3 program for early Alzheimer's disease.

At an H.C. Wainwright conference on September 14, 2026, Investing.com reported that management cited a 70 percent reduction in itch severity and more than 200 CORDStrom administrations without a serious adverse event. The same report said the UK filing is planned for Q4 2026, making regulatory execution the next measurable checkpoint.

Q2 loss narrows to USD 1.3 million

For Q2 2026, INmune Bio posted a net loss of USD 1.3 million and held USD 18.4 million in cash at June 30, 2026, according to The Desperate Trader. The loss was materially lower than the USD 24.5 million loss cited for the year-earlier period, although the source labels the comparative period as Q2 FY2026.

GAAP earnings per share came in at a loss of USD 0.05, versus consensus for a loss of USD 0.20, a USD 0.15 improvement against expectations, according to BusinessQuant. That quarterly comparison gives the stock a financial counterweight to its development-stage risk.

Stock remains near its yearly range

INmune Bio stock carried a market capitalization of USD 51.3 million and volume of 290,237 shares on October 2, 2026. The session range was USD 1.93 to USD 2.00, while the 52-week range extended from USD 1.09 to USD 2.60.

The valuation picture remains tied to clinical and regulatory milestones rather than established commercial sales. For investors, the central question is whether the planned filing schedule can convert the reported CORDStrom data into a reviewable application.